Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused
ENROLLING_BY_INVITATION
This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC